首页>投融资
Eledon Pharmaceuticals
上市后再融资
Eledon Pharmaceuticals, Inc.于2004年3月26日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于开发针对于前列腺癌和其他激素驱动的疾病的治疗的新的专有疗法。公司目前专注于其在最初的阉割性前列腺癌的治疗或CRPC，它的前列腺肿瘤细胞表达了被截断的雄激素受体的改变。
基本信息
-
公司全称Eledon Pharmaceuticals Inc
-
类型小分子药物研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15~50人
-
地址19900 MacArthur Boulevard Suite 550 Irvine California
-
联系电话1-949-2388090
-
邮箱caton@purecommunicationsinc.com
-
成立时间2004-01-01
投融资
-
2024-10-30上市后再融资8500万美元JDRF T1D FundNantahala Capital ManagementWoodline PartnersSphera Global Healthcare FundFirst Light Asset ManagementBlue Owl CapitalFrazier ManagementRA CapitalBVF Partners
-
2024-05-09上市后再融资5000万美元未透露
-
2023-05-01上市后再融资1.85亿美元BVF PartnersArmistice Capital赛诺菲
-
2014-09-17上市9039.6万美元未透露
-
2013-05-15E~PreIPO3550万美元诺华Apple Tree Partners
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息